國立高雄大學圖資館 |

Language: English

Back

Relationship between Quality of Life...

Ford-Scheimer, Stephanie L.

Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers.
Author:	Ford-Scheimer, Stephanie L.
Published:	Ann Arbor : ProQuest Dissertations & Theses, 2017
Description:	123 p.
Notes:	Source: Dissertation Abstracts International, Volume: 78-06(E), Section: B.
Notes:	Adviser: Diana Naser.
Contained By:	Dissertation Abstracts International78-06B(E).
Subject:	Epidemiology.
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10256285
ISBN:	9781369552393

Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers.
Ford-Scheimer, Stephanie L.

Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers. - Ann Arbor : ProQuest Dissertations & Theses, 2017 - 123 p.

Source: Dissertation Abstracts International, Volume: 78-06(E), Section: B.

Thesis (Ph.D.)--Walden University, 2017.

Research in the field of neuroendocrine tumors (NETs) has increased over the last decade, including studies focused on biochemical markers (biomarkers) of the disease. There is also growing interest in how NETs impact patients' quality of life (QOL). Consequently, there is a paucity of information about whether the expression of the specific disease biomarkers affects QOL as well as whether the primary tumor site impacts QOL. Using the explanatory model of health promotion and quality of life in chronic disabling conditions as the theoretical framework and data collected with the Norfolk QOL-NET instrument, this study's purpose was to fill that gap in knowledge through research questions addressing the relationship between the primary tumor site and NET patients' total QOL score as well as the effect of specific NET biomarkers on NET patients' total QOL score. Data were analyzed using descriptive statistics, one-way analysis of variance (ANOVA), regression analysis, and post hoc tests to determine significance. Results from an ANOVA showed that abnormal NET biomarkers affected total QOL (p = 0.011). In the analyses of whether the independent biomarker variables affected the dependent total QOL variable, only the result for Serotonin Normal was significant (p = 0.002). The presence of abnormal biomarker measurements also affected two of the Norfolk QOL-NET domains significantly, gastrointestinal and physical functioning (p = 0.005 and p = 0.030, respectively). By understanding the relationship between NETs and patient QOL, the potential positive social change implications are helping NET patients assess the severity of their condition, determining what affects their well-being, and using this information to help monitor their treatment/progress.

ISBN: 9781369552393Subjects--Topical Terms:

191577
Epidemiology.

Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers.
LDR:02715nmm a2200289 4500 001 523875
005 20180517120323.5
008 180709s2017 ||||||||||||||||| ||eng d
020 $a 9781369552393
035 $a (MiAaPQ)AAI10256285
035 $a (MiAaPQ)waldenu:18521
035 $a AAI10256285
040 $a MiAaPQ $c MiAaPQ
100 1 $a Ford-Scheimer, Stephanie L. $3 795320
245 1 0 $a Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 123 p.
500 $a Source: Dissertation Abstracts International, Volume: 78-06(E), Section: B.
500 $a Adviser: Diana Naser.
502 $a Thesis (Ph.D.)--Walden University, 2017.
520 $a Research in the field of neuroendocrine tumors (NETs) has increased over the last decade, including studies focused on biochemical markers (biomarkers) of the disease. There is also growing interest in how NETs impact patients' quality of life (QOL). Consequently, there is a paucity of information about whether the expression of the specific disease biomarkers affects QOL as well as whether the primary tumor site impacts QOL. Using the explanatory model of health promotion and quality of life in chronic disabling conditions as the theoretical framework and data collected with the Norfolk QOL-NET instrument, this study's purpose was to fill that gap in knowledge through research questions addressing the relationship between the primary tumor site and NET patients' total QOL score as well as the effect of specific NET biomarkers on NET patients' total QOL score. Data were analyzed using descriptive statistics, one-way analysis of variance (ANOVA), regression analysis, and post hoc tests to determine significance. Results from an ANOVA showed that abnormal NET biomarkers affected total QOL (p = 0.011). In the analyses of whether the independent biomarker variables affected the dependent total QOL variable, only the result for Serotonin Normal was significant (p = 0.002). The presence of abnormal biomarker measurements also affected two of the Norfolk QOL-NET domains significantly, gastrointestinal and physical functioning (p = 0.005 and p = 0.030, respectively). By understanding the relationship between NETs and patient QOL, the potential positive social change implications are helping NET patients assess the severity of their condition, determining what affects their well-being, and using this information to help monitor their treatment/progress.
590 $a School code: 0543.
650 4 $a Epidemiology. $3 191577
690 $a 0766
710 2 $a Walden University. $b Public Health. $3 795321
773 0 $t Dissertation Abstracts International $g 78-06B(E).
790 $a 0543
791 $a Ph.D.
792 $a 2017
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10256285